Pay in 4 interest-free payments of $21.25 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
AR7 is the first small molecule developed to selectively stimulate CMA without affecting macroautophagy
) is well tolerated
25(3):473-81
higher doses than those required for anticonvulsant efficacy of the drugs were needed for activity in the reversal-learning model
CC-930 inhibits the formation of phospho-cJun in human PBMC stimulated by phorbol-12-myristate-13-acetate and phytohemeagglutinin (IC50=1 μM)
TAK-960 - CAS# 1137868-52-0 Catalog No.:M6675-10 AR7 is the first smallTAK 960, CAS No. 1137868 52 0, is a n orally available PLK1 inhibitor with potential antineoplastic activity. Polo like kinase 1 inhibitor TAK 960 selectively inhibits PLK1, inducing selective G2 M cell cycle arrest followed by apoptosis in a variety of tumor cells while causing reversible cell cycle arrest at the G1 and G2 stages without apoptosis in normal cells. PLK1 inhibition may result in the inhibition of proliferation in PLK1 overexpressed
US$ 113.00
US$ 105.00
US$ 89.90
US$ 175.30
US$ 16.40